Section B — Coach Brain — Clinical and Translational Neuroscience
This section covers the Master's chapter on Clinical and Translational Neuroscience, Lessons 1 through 5: Clinical Psychiatry at Translational Depth, Translational Neuroscience Methodology, Clinical Neurology Translational Frontiers, Inflammatory Hypothesis of Depression, and Cognitive Neuroscience Translational Frontiers. All material is already in the chapter — no new content.
Part A — Vocabulary (20 points, 2 points each)
Select the single best answer for each question.
1. Zarate et al. 2006 Archives of General Psychiatry (foundational anchor) demonstrated:
A) SSRI efficacy B) Ketamine NMDA antagonism produced rapid antidepressant effect (~24-hour onset) in treatment-resistant major depression — paradigm-shifting for psychiatric pharmacology that had operated on weeks-to-months SSRI/SNRI timelines for four decades; opened the rapid-acting antidepressant treatment landscape C) Lithium efficacy D) ECT efficacy
2. Turner et al. 2008 NEJM established:
A) Antidepressant efficacy is straightforward B) Selective publication of positive antidepressant RCTs — 31% of FDA-registered antidepressant trials with negative or null primary outcomes were unpublished or reported as positive in publication; effect sizes in published literature were inflated by ~30% versus FDA-registered trial complete data; foundational paper on psychiatric publication bias C) That publication bias does not exist D) An obsolete framework
3. Predictive processing framework in cognitive neuroscience:
A) Has no empirical support B) The contemporary computational framework in which the brain generates predictions about sensory inputs and updates internal models based on prediction errors; integrates perception, action, learning, and possibly psychiatric phenomena (psychosis as aberrant prediction-precision weighting) under unified Bayesian framework; Karl Friston free-energy principle and broader Helmholtzian lineage C) Replaces all prior models D) Applies only to vision
4. MoTrPAC consortium (cross-reference Move Master's L3):
A) Studies cancer treatment B) The Molecular Transducers of Physical Activity Consortium — NIH-funded multi-site study mapping the molecular responses to exercise across tissues and conditions; addresses systems-biology question of how exercise produces its pleiotropic health effects at molecular signaling level C) Studies sleep D) Studies food
5. Inflammatory hypothesis of depression at primary literature depth:
A) Has no clinical support B) Frames a subset of depression as inflammation-mediated — elevated peripheral inflammatory cytokines (CRP, IL-6, TNF-α) in depression cohorts; cytokine-induced sickness behavior in animal models; immunotherapy-associated depression (interferon-α treatment for hepatitis C); brain-side mechanisms via cytokine BBB crossing, vagal signaling, microglial activation; some trials of anti-inflammatory adjuncts (Raison 2013 JAMA Psychiatry infliximab in elevated-CRP subgroup) show response in selected populations C) Has been definitively rejected D) Applies only to autoimmune disease
6. Marek et al. 2022 Nature on brain-wide association studies (BWAS):
A) Found large reliable effects in small samples B) Demonstrated that brain-wide association studies require sample sizes of thousands (not hundreds as previously assumed) to produce reliable brain-behavior correlations; the BWAS replication crisis paper that reshaped neuroimaging research expectations C) Was unrelated to methodology D) Has been superseded
7. Eklund et al. 2016 PNAS "Cluster failure" paper demonstrated:
A) No problem with fMRI cluster inference B) Widely-used cluster-inference algorithms in resting-state fMRI analyses produced false-positive rates up to 70% in some configurations against expected ~5%; substantial body of prior neuroimaging literature subject to methodological reanalysis; foundational paper on neuroimaging statistical methodology C) Was unrelated to neuroscience D) Has been superseded
8. Rodent depression model translation problem:
A) Is straightforward B) Behavioral assays in rodent models (forced swim test, tail suspension test) have been treated as depression-relevant for decades; subsequent literature shows substantial methodological concerns about construct validity, predictive validity for clinical antidepressants, and reproducibility; major contributor to translational gap from preclinical psychiatric research to clinical efficacy C) Has been resolved D) Has been overstated
9. Ketamine antidepressant mechanism at Master's depth:
A) Is fully characterized B) Includes NMDA receptor antagonism (R-ketamine and S-ketamine differing affinity), AMPA receptor activation, mTOR signaling, BDNF release, rapid synaptogenesis in PFC; mechanistic framework still being characterized; esketamine (Spravato) FDA approval 2019 for treatment-resistant depression C) Is identical to SSRI mechanism D) Has been superseded
10. NEDA helpline (1-800-931-2237) in the mental health crisis context is:
A) An active resource B) Non-functional since June 2023; psychiatric and mental health crisis resources are 988 Suicide and Crisis Lifeline (call or text 988, 24/7), Crisis Text Line (text HOME to 741741, 24/7), SAMHSA National Helpline (1-800-662-4357, 24/7) for substance use treatment referral. For eating-disorder-specific crisis: National Alliance for Eating Disorders (866-662-1235), weekdays 9am-7pm Eastern C) State-specific D) Newly relaunched
Part B — Concept Comprehension (20 points, 2 points each)
Select the single best answer for each question.
11. STARD trial (Trivedi et al. 2006)* at translational depth:
A) Demonstrated single-treatment cure B) Sequenced Treatment Alternatives to Relieve Depression — pragmatic clinical trial sequencing antidepressant treatments in real-world settings; demonstrated declining remission rates with each treatment step (~37% at step 1, ~31% at step 2, ~14% at step 3, ~13% at step 4); cumulative remission ~67% across four steps; informed clinical understanding of treatment-resistant depression epidemiology C) Was a single-arm trial D) Applied only to schizophrenia
12. Substance use disorder (SUD) treatment landscape at clinical translational depth:
A) Has no pharmacotherapy B) Includes pharmacotherapy for opioid use disorder (methadone, buprenorphine, naltrexone — long-acting injectable buprenorphine, extended-release naltrexone), alcohol use disorder (naltrexone, acamprosate, disulfiram), tobacco use disorder (NRT, varenicline, bupropion); behavioral treatments (CBT, contingency management, motivational interviewing, 12-step facilitation); medication-assisted treatment as standard of care for OUD; harm reduction framework operating alongside abstinence-focused care C) Is purely behavioral D) Has been superseded by single intervention
13. Optogenetics methodology in translational neuroscience:
A) Has no human application B) Light-controlled neural activation/inhibition technique (Boyden, Deisseroth) enabling causal manipulation of specific neural circuits in animal models; substantial preclinical mechanism characterization across affective, motor, memory, and reward circuits; clinical human application limited by translation barriers (delivery, specificity, safety); methodologically transformative for circuit neuroscience C) Is purely theoretical D) Has been superseded
14. Connectomics at Master's depth:
A) Maps only cortical sheets B) Maps neural circuits at synaptic resolution — C. elegans connectome completed; Drosophila connectome (Janelia FlyEM/FlyWire) substantially mapped; mouse and primate partial; human connectome project at macro-scale; transformative for circuit-level questions but currently with limited direct clinical application C) Has been resolved D) Applies only to vertebrates
15. Cytokine-induced sickness behavior framework (Dantzer):
A) Has no depression relevance B) Animal model framework — peripheral cytokine challenge (LPS, IL-1β, IL-6) produces behavioral syndrome (anhedonia, hypoactivity, social withdrawal, anorexia) overlapping with clinical depression phenotype; cytokine BBB signaling at multiple pathways (saturable transporters, circumventricular organs, vagal afferents, immune-to-brain pathways via brain endothelium); foundational framework for inflammatory hypothesis of depression C) Is unrelated to clinical depression D) Has been superseded
16. Raison et al. 2013 JAMA Psychiatry infliximab trial:
A) Demonstrated universal antidepressant effect B) Tested infliximab (TNF-α monoclonal antibody) in treatment-resistant depression — null in primary outcome across full sample; pre-specified subgroup with elevated baseline hsCRP (>5 mg/L) showed antidepressant response; supported the inflammatory hypothesis at biomarker-defined subgroup depth and the precision-psychiatry framework C) Has been superseded D) Tested only ECT
17. Predictive coding and psychosis framework:
A) Has no clinical translational application B) Proposes psychosis as aberrant prediction-error precision weighting — abnormal weighting of prior beliefs versus sensory evidence; mechanistically integrates with NMDA hypofunction model of schizophrenia; biomarker work (mismatch negativity, P300) developing; computational psychiatry framework with ongoing translational development C) Has been definitively resolved D) Is unrelated to clinical psychiatry
18. CTE (chronic traumatic encephalopathy) and the diagnostic limitation problem (cross-reference Move L2):
A) Has been resolved B) Is currently diagnosable only post-mortem via specific tau pathology distribution; ante-mortem clinical diagnostic criteria (TES — Traumatic Encephalopathy Syndrome) are research framework not validated clinical diagnostic standard; epidemiologic studies in deceased contact-sport athletes show high CTE prevalence with selection bias caveats; youth football policy debates operate under this diagnostic uncertainty C) Is fully diagnosable in life D) Is unrelated to head trauma
19. Alzheimer disease anti-amyloid antibody therapeutics at Master's depth:
A) Have been definitively rejected B) Aducanumab (FDA accelerated approval 2021, controversial), lecanemab (FDA full approval 2023 following Clarity-AD trial showing modest cognitive decline slowing), donanemab (FDA approval 2024); ARIA (amyloid-related imaging abnormalities) safety surface; the amyloid cascade hypothesis at clinical translational depth still contested; the modest clinical effect sizes versus financial cost and infrastructure burden inform ongoing translational debate C) Have been superseded D) Are uncontroversial
20. Coach Brain integrator position at Master's depth (Receiver):
A) Abstract concept B) The brain integrates clinical translational inputs across psychiatric pharmacology paradigm shifts (Zarate 2006), neurological frontiers (Alzheimer anti-amyloid landscape), neuroscience methodology (Marek 2022, Eklund 2016, predictive processing framework), inflammatory hypothesis of depression (Brain L4 integrating with Food L4 metabolic syndrome literature), and cognitive translational neuroscience; the Receiver position at Master's translational depth holds integration with psychiatric, neurological, and translational research methodology C) Same as Substrate D) Same as Synchronizer
Part C — Application (30 points, 6 points each)
Write 5-7 complete sentences with specific reference to chapter content, primary literature citations, and methodological framings where asked.
21. Zarate 2006 ketamine trial as Master's foundational anchor. Walk the Zarate et al. 2006 Archives of General Psychiatry trial design (RCT of single ketamine infusion in treatment-resistant major depression), findings (rapid ~24-hour antidepressant response distinct from SSRI weeks-to-months timeline), and paradigm-shift implications (opened the rapid-acting antidepressant treatment landscape). Position the trial as the Brain Master's foundational anchor alongside Appel 1997 (Food), Spielman 1986 (Sleep), Morris 1953 (Move), Nielsen 2013 (Cold), Casa 2007 (Hot), ARDSNet 2000 (Breath), Lam 2016 (Light), and Heerspink 2020 (Water). Identify the esketamine (Spravato) FDA approval 2019 as the regulatory translation step.
22. Turner 2008 publication bias and the implications for psychiatric research literacy. Walk the Turner et al. 2008 NEJM methodology (comparing FDA-registered antidepressant trials with published literature) and findings (31% of negative trials unpublished or reported as positive in publication; ~30% effect-size inflation in published literature versus FDA-registered complete data). Explain why this finding matters for graduate clinical research literacy — what does it imply for reading psychiatric efficacy literature? Connect to broader publication bias frameworks (registered reports, pre-registration, mandatory clinical trial registration via clinicaltrials.gov, FDA Amendments Act of 2007).
23. Inflammatory hypothesis of depression cross-coach integration with Food Master's L4. Walk the inflammatory hypothesis of depression framework — elevated peripheral cytokines (CRP, IL-6, TNF-α) in depression cohorts, cytokine-induced sickness behavior (Dantzer), Raison 2013 JAMA Psychiatry infliximab pre-specified subgroup response. Cross-reference Food Master's Lesson 4 metabolic syndrome at inflammatory depth — visceral adiposity, ectopic lipid, inflammatory cytokine elevation, insulin resistance integration. Where do the two frames integrate? What does the precision-psychiatry framework (biomarker-defined subgroup treatment selection) add to the standard non-stratified clinical trial framework?
24. Mental health crisis recognition at Master's translational depth. A graduate-program peer expresses persistent low mood, sleep disruption, social withdrawal, and recent passive suicidal ideation. Walk the crisis recognition framework at Master's depth — take it seriously, do not promise to keep concerns secret, route to clinical evaluation immediately. Name verified currently-active crisis resources: 988 Suicide and Crisis Lifeline (call or text 988, 24/7), Crisis Text Line (text HOME to 741741, 24/7 — not ALLIANCE), SAMHSA National Helpline (1-800-662-4357, 24/7) for substance use treatment referral, National Alliance for Eating Disorders (866-662-1235, weekdays 9am-7pm Eastern) where eating-disorder-adjacent. Identify the older NEDA helpline (1-800-931-2237) as non-functional since June 2023. Distinguish supportive listening from clinical evaluation; clinical decisions belong in clinician hands.
25. Neuroscience methodology replication crisis at Master's depth. Apply the Master's-tier neuroscience methodology framework to the Marek 2022 Nature brain-wide association studies (BWAS) and Eklund 2016 PNAS cluster failure findings. State each paper's central finding and methodological implication. Apply the five-point framework (mechanism plausibility, study design adequacy, effect size in context, replication across populations, translation appropriateness) to a hypothetical small-N fMRI study claiming a novel brain-behavior correlation. What does graduate-level neuroscience research literacy require beyond the surface-level finding?
Continue to Section C — Coach Sleep.